We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Elimination of CSCs as Potential Cure for Colon Cancer

By LabMedica International staff writers
Posted on 29 Jan 2018
Cancer researchers have identified a molecular pathway required by the cancer stem cells that underlie growth and development of colorectal tumors.

Colon cancer is a heterogeneous tumor driven by a subpopulation of cancer stem cells (CSCs). More...
To study CSCs in colon cancer, investigators at Charité - Universitätsmedizin Berlin, Germany) used limiting dilution spheroid and serial xenotransplantation assays in mice to functionally define the frequency of CSCs in a panel of patient-derived cancer organoids. The aim was to eventually arrive at a treatment option that would cure colon cancer through the targeted elimination of cancer stem cells.

Results published in the December 5, 2017, issue of the journal Cell Reports showed that cancer organoids were enriched for CSCs, which varied in frequency between tumors. Whole-transcriptome analysis identified the WNT and Hedgehog signaling pathways as being enhanced in CSC-enriched tumors and in aldehyde dehydrogenase (ALDH)-positive CSCs. Furthermore, they showed that non-canonical Hedgehog signaling was a positive regulator of WNT signaling and was required for colon CSC survival.

"The targeted inhibition of the Hedgehog signaling pathway, used in combination with other standard treatments to shrink tumors, may provide a new strategy for the elimination of cancer stem cells and the prevention of cancer recurrence," said first author Dr. Joseph Regan, a researcher at Charité - Universitätsmedizin Berlin. "Future research will set out to better define the downstream signaling components of the pathway and further investigate how Hedgehog signaling controls cancer stem cell survival."

Related Links:
Charité - Universitätsmedizin Berlin


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.